Last reviewed · How we verify
MenACYW135 polysaccharide vaccine
MenACYW135 polysaccharide vaccine is a Conjugate polysaccharide vaccine Biologic drug developed by Sanofi. It is currently in Phase 3 development for Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, and Y.
MenACYW135 is a conjugate vaccine that stimulates the immune system to produce antibodies against meningococcal serogroups A, C, W, and Y polysaccharide antigens.
MenACYW135 is a conjugate vaccine that stimulates the immune system to produce antibodies against meningococcal serogroups A, C, W, and Y polysaccharide antigens. Used for Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, and Y.
At a glance
| Generic name | MenACYW135 polysaccharide vaccine |
|---|---|
| Sponsor | Sanofi |
| Drug class | Conjugate polysaccharide vaccine |
| Target | Neisseria meningitidis serogroups A, C, W, Y polysaccharide capsules |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
The vaccine contains purified polysaccharide capsules from Neisseria meningitidis serogroups A, C, W, and Y conjugated to a protein carrier (typically diphtheria toxoid or CRM197), which enhances immunogenicity and T-cell dependent immune response. This conjugation allows for improved antibody production and immunological memory compared to unconjugated polysaccharide vaccines, providing protection against invasive meningococcal disease caused by these four serogroups.
Approved indications
- Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, and Y
Common side effects
- Injection site pain/erythema
- Headache
- Myalgia
- Fatigue
- Fever
Key clinical trials
- Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Healthy Children and Adolescents in China (PHASE3)
- Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MenACYW135 polysaccharide vaccine CI brief — competitive landscape report
- MenACYW135 polysaccharide vaccine updates RSS · CI watch RSS
- Sanofi portfolio CI
Frequently asked questions about MenACYW135 polysaccharide vaccine
What is MenACYW135 polysaccharide vaccine?
How does MenACYW135 polysaccharide vaccine work?
What is MenACYW135 polysaccharide vaccine used for?
Who makes MenACYW135 polysaccharide vaccine?
What drug class is MenACYW135 polysaccharide vaccine in?
What development phase is MenACYW135 polysaccharide vaccine in?
What are the side effects of MenACYW135 polysaccharide vaccine?
What does MenACYW135 polysaccharide vaccine target?
Related
- Drug class: All Conjugate polysaccharide vaccine drugs
- Target: All drugs targeting Neisseria meningitidis serogroups A, C, W, Y polysaccharide capsules
- Manufacturer: Sanofi — full pipeline
- Therapeutic area: All drugs in Immunology / Infectious Disease
- Indication: Drugs for Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, and Y
- Compare: MenACYW135 polysaccharide vaccine vs similar drugs
- Pricing: MenACYW135 polysaccharide vaccine cost, discount & access